Logo

Affy Partners with Imperial College London, MRC to Genotype Heart Disease, Diabetes, and Cancer

Dec 14, 2005

NEW YORK, Dec. 14 (GenomeWeb News) - Affymetrix said today that researchers at Imperial College London and the UK's Medical Research Council will use the company's GeneChip technology to study the genetic variations associated with cancer, cardiovascular disease, and diabetes.

 

The researchers will use Affy arrays to perform genotyping and gene-expression experiments. Affymetrix did not disclose which of its GeneChips the UK researchers will use.

 

Affymetrix said that the collaboration is part of its translational medicine program, an initiative designed to "accelerate clinical research and improve patient care by helping to bring more effective personalized tests and therapies to market faster."

 

Financial terms of the agreement were not provided.

Breaking News
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.